CD8A and neoplasm: However, PD-1, TIGIT, and CTLA-4 are highly expressed in the TILs of TNBC patients, while PD-L1 and CD155 ligands are highly expressed in tumor cells or antigen presenting cells (APCs), which may make CD8+ T cells inefficient at killing tumor cells [30].